| Autor: |
Grootjen LN; Dutch Reference Center for Prader-Willi Syndrome, 3015 CN Rotterdam, The Netherlands.; Department of Pediatrics, Subdivision of Endocrinology, Erasmus University Medical Center-Sophia Children's Hospital, 3015 CN Rotterdam, The Netherlands.; Dutch Growth Research Foundation, 3016 AH Rotterdam, The Netherlands., Trueba-Timmermans DJ; Dutch Reference Center for Prader-Willi Syndrome, 3015 CN Rotterdam, The Netherlands.; Department of Pediatrics, Subdivision of Endocrinology, Erasmus University Medical Center-Sophia Children's Hospital, 3015 CN Rotterdam, The Netherlands.; Dutch Growth Research Foundation, 3016 AH Rotterdam, The Netherlands., Damen L; Dutch Reference Center for Prader-Willi Syndrome, 3015 CN Rotterdam, The Netherlands.; Department of Pediatrics, Subdivision of Endocrinology, Erasmus University Medical Center-Sophia Children's Hospital, 3015 CN Rotterdam, The Netherlands.; Dutch Growth Research Foundation, 3016 AH Rotterdam, The Netherlands., Mahabier EF; Dutch Reference Center for Prader-Willi Syndrome, 3015 CN Rotterdam, The Netherlands.; Dutch Growth Research Foundation, 3016 AH Rotterdam, The Netherlands., Kerkhof GF; Dutch Reference Center for Prader-Willi Syndrome, 3015 CN Rotterdam, The Netherlands.; Department of Pediatrics, Subdivision of Endocrinology, Erasmus University Medical Center-Sophia Children's Hospital, 3015 CN Rotterdam, The Netherlands., Hokken-Koelega ACS; Dutch Reference Center for Prader-Willi Syndrome, 3015 CN Rotterdam, The Netherlands.; Department of Pediatrics, Subdivision of Endocrinology, Erasmus University Medical Center-Sophia Children's Hospital, 3015 CN Rotterdam, The Netherlands.; Dutch Growth Research Foundation, 3016 AH Rotterdam, The Netherlands. |
| Abstrakt: |
Long-term effects of growth hormone (GH) treatment in young children with Prader-Willi syndrome (PWS) have never been compared with untreated age-matched controls with PWS, and it is unclear if starting GH in the first year of life is safe and more effective than starting GH in early childhood. We investigated the effects of long-term GH on body composition, anthropometrics and cognition in young children with PWS compared to untreated controls and assessed whether starting GH in the first year of life is optimal and safe. An open-label, prospective study was performed, comparing GH-treated children with untreated controls, and comparing children who started GH in the first year of life (subgroup A) with children who started between 2-5 years (subgroup C). A total of 82 GH-treated children with PWS and 22 age-matched controls with PWS were included. The main outcome measures were body composition, anthropometrics, IQ, and safety parameters. After 8 years, GH-treated children had significantly better body composition and were taller than age-matched controls. Subgroup A had a lower FM% trajectory during treatment than subgroup C and showed a greater and longer-term increase in the LBM index. After 8 years, subgroup A had a lower trunk/peripheral fat ratio ( p = 0.043) and higher IQ ( p = 0.043). No adverse effects of starting GH in the first year were found. Children with PWS who received long-term GH had a better body composition and growth than untreated age-matched controls and starting GH in the first year of life was optimal and safe. |
